ABSTRACT
Introduction “Metabolic Dysfunction-Associated Steatotic Pancreas Disease” (MASPD) is not yet a term or condition described in the medical literature. The MASPD is a relatively new and emerging condition that has garnered significant attention in the field of metabolic disorders.
Objective to investigate the association between MASPD and IR and explore the potential mechanisms that may contribute to this relationship.
Materials and Methods This cross-sectional study involved 157 participants diagnosed with MASPD based on ultrasonography criteria. Baseline demographic data were collected, including age, gender, and body mass index. Serum levels of fasting glucose, insulin, lipid profile (including total cholesterol, triglycerides, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol), glycated hemoglobin and insulin were measured using standardized laboratory techniques. Abdominal ultrasonography was performed on all participants using convex transducer (frequency range, 3,5 MHz) by experienced radiologist blinded to the clinical data. The association between MASPD and IR was assessed using logistic regression analysis, adjusting for potential confounders. Statistical significance was set at a p-value of less than 0.05.
Results The logistic regression analysis was performed to verify whether IR was a risk factor for MASPD. After adjusting for gender and age, the results demonstrate a significant correlation between MDASPD and markers of IR. TyG index: OR (95% IC) 5.72 (1.90 – 16.00), P 0.021, and HOMA –IR: OR (95% IC) 6.20 (2.1 – 22.00) P 0.037.
Conclusion This study presents the first description of MDASPD and its association with IR indices. Our findings demonstrate a significant correlation between MDASPD and markers of IR. These results suggest that MDASPD may contribute to the development of insulin resistance and further highlight the importance of pancreatic health in metabolic disorders.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was conducted in accordance with the principles outlined in the Declaration of Helsinki. The study protocol The National Commission for Research Ethics (CONEP - Brazil) approved the project (registry number: 2.464.513) was approved by The National Commission for Research Ethics (CONEP - Brazil), and written informed consent was obtained from all participants prior to their inclusion in the study. Confidentiality of personal information was strictly maintained throughout the study, and all data were analyzed and reported in an aggregated and anonymized manner.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
